Asahi Kasei Pharma has started enrolling patients in a Phase III trial of isavuconazole to treat deep-seated mycosis, comprised of invasive aspergillosis, chronic pulmonary aspergillosis, mucormycosis and cryptococcosis.

The randomised, multi-centre trial is designed to evaluate the safety and efficacy of intravenously (i.v.) or orally administered isavuconazole versus i.v. or oral voriconazole as an active comparator in the treatment of patients with deep-seated mycosis.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It aims to enrol around 100 adult patients in Japan.

“Invasive fungal infections can be life-threatening and are an area of significant medical need worldwide.”

Part of an abbreviated development programme, the trial is the result of a licence agreement signed between Asahi Kasei Pharma and Switzerland’s Basilea Pharmaceutica International in 2016.

The agreement gives Asahi Kasei Pharma exclusive rights to develop and commercialse Basilea’s isavuconazole in Japan.

Depending on the successful completion of the Phase III trial, Asahi Kasei Pharma plans to submit a marketing authorisation application for isavuconazole in Japan.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Basilea Pharmaceutica CEO Ronald Scott said: “Invasive fungal infections can be life-threatening and are an area of significant medical need worldwide.

“Basilea is working together with its partners to bring isavuconazole to patients around the world.”

Isavuconazole is an oral azole antifungal, commercialised under the brand name of Cresemba.

The drug is currently available under various licence and distribution agreements in the US, Europe, China, Japan, Latin America, Canada, Russia, Turkey, Israel, the Asia-Pacific, Middle East and North Africa regions.

In the US, isavuconazole is approved for the treatment of patients aged 18 and older for invasive aspergillosis and invasive mucormycosis. However, it is not approved for commercial use outside the US and Europe.